Skip to main content

National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum: 20 Years of Research Informing Practice

Addiction Science & Clinical Practice is pleased to announce an upcoming special series on the opioid use disorder (OUD) care continuum, specifically articles describing broad research and data supported by the National Drug Abuse Treatment Clinical Trials Network (CTN): its past effort in developing MOUD treatment and current effort in improving MOUD treatment quality. The series will commemorate 20 years of CTN research activities are be guest edited by:

E. Jennifer Edelman, MD, MHS, Yale University, USA
Andrew J. Saxon, MD, University of Washington, USA

This thematic series will highlight in an open-access format articles focusing on identification of OUD, access and linkage to care, medication and other treatment initiation, treatment retention (including tools that promote retention in care via technology, contingency management, etc.), research-practice gaps, and quality of care, as well as the impact of COVID-19 on the OUD care continuum. The series will welcome all manuscript submissions on these topics (including study protocols) from CTN-supported researchers and those who work with CTN-supported data.

ASCP is an open-access, Medline and PsycINFO-listed journal. It provides a forum for clinically relevant research and perspectives that contribute to improving the quality of care for people with unhealthy alcohol, tobacco, or other drug use and addictive behaviors across a spectrum of clinical settings. It is published by BMC, part of Springer Nature and a leader in the field of open-access publishing.

CTN was established by the National Institute on Drug Abuse (NIDA) to bridge the gap between substance use disorder research and clinical practice.

Funding for the article-processing charge is available thanks to the generosity of NIDA CTN. This is subject to editorial acceptance and will be offered while funds are available. All submissions to ASCP are subject to editorial and peer review.

CTN policy requires papers to be reviewed in the CTN Publications Committee (PC), prior to being submitted to ASCP. To participate in the issue, email your manuscript to Jack Blaine ( and George Bigelow ( with a copy to Udi Ghitza ( and Landhing Moran ( in the Center for the Clinical Trials Network for review and approval.

Submissions will be reviewed on a rolling basis upon receipt and are requested through the fall of 2020. They should be submitted to the CTN PC prior to this deadline. The original deadline has been extended due to the impact of COVID-19 on research activities. All CTN-approved submissions will be subject to standard peer-review and editorial policies and will be published at the discretion of the Editors-in-Chief. If any guest editors author an article, they will not handle the peer review process.

  1. The CHOICES study randomized participants with HIV and opioid use disorder (OUD) to HIV clinic-based extended-release naltrexone (XR-NTX), which requires complete cessation of opioid use, versus treatment-as-u...

    Authors: Kim A. Hoffman, Robin Baker, Laura C. Fanucchi, Paula J. Lum, Lynn E. Kunkel, Javier Ponce Terashima, Dennis McCarty, Petra Jacobs and P. Todd Korthuis
    Citation: Addiction Science & Clinical Practice 2021 16:67
  2. The emergency department (ED) offers an important opportunity to identify patients with opioid use disorder (OUD) and initiate treatment. However, post-ED follow-up is challenging, and novel approaches to enha...

    Authors: Kathryn Hawk, Caitlin Malicki, Jeremiah Kinsman, Gail D’Onofrio, Andrew Taylor and Arjun Venkatesh
    Citation: Addiction Science & Clinical Practice 2021 16:66
  3. Little is known about prevalence and treatment of OUD among youth engaged in primary care (PC). Medications are the recommended treatment of opioid use disorder (OUD) for adolescents and young adults (youth). ...

    Authors: Sarah M. Bagley, Laura Chavez, Jordan M. Braciszewski, Mary Akolsile, Denise M. Boudreau, Gwen Lapham, Cynthia I. Campbell, Gavin Bart, Bobbi Jo H. Yarborough, Jeffrey H. Samet, Andrew J. Saxon, Rebecca C. Rossom, Ingrid A. Binswanger, Mark T. Murphy, Joseph E. Glass and Katharine A. Bradley
    Citation: Addiction Science & Clinical Practice 2021 16:46
  4. Over the past two decades, the National Drug Abuse Treatment Clinical Trials Network (CTN), a program of the National Institute on Drug Abuse (NIDA), has expanded from the initial six Nodes to 16 Nodes, as a n...

    Authors: Betty Tai, Ronald Dobbins, Quandra Blackeney, David Liu and Landhing Moran
    Citation: Addiction Science & Clinical Practice 2021 16:28
  5. Telemedicine (TM) enabled by digital health technologies to provide medical services has been considered a key solution to increasing health care access in rural communities. With the immediate need for remote...

    Authors: Yih-Ing Hser, Allison J. Ober, Alex R. Dopp, Chunqing Lin, Katie P. Osterhage, Sarah E. Clingan, Larissa J. Mooney, Megan E. Curtis, Lisa A. Marsch, Bethany McLeman, Emily Hichborn, Laurie S. Lester, Laura-Mae Baldwin, Yanping Liu, Petra Jacobs and Andrew J. Saxon
    Citation: Addiction Science & Clinical Practice 2021 16:24
  6. For many reasons, the emergency department (ED) is a critical venue to initiate OUD interventions. The prevailing culture of the ED has been that substance use disorders are non-emergent conditions better addr...

    Authors: Ryan P. McCormack, John Rotrosen, Phoebe Gauthier, Gail D’Onofrio, David A. Fiellin, Lisa A. Marsch, Patricia Novo, David Liu, E. Jennifer Edelman, Sarah Farkas, Abigail G. Matthews, Caroline Mulatya, Dagmar Salazar, Jeremy Wolff, Randolph Knight, William Goodman…
    Citation: Addiction Science & Clinical Practice 2021 16:16
  7. Opioid use disorder continues to be a significant problem in the United States and worldwide. Three medications—methadone, buprenorphine, and extended-release injectable naltrexone,— are efficacious for treati...

    Authors: Matisyahu Shulman, Roger Weiss, John Rotrosen, Patricia Novo, Elizabeth Costello and Edward V. Nunes
    Citation: Addiction Science & Clinical Practice 2021 16:15
  8. The treatment capacity for opioid use disorder (OUD) lags far behind the number of patients in need of treatment. Capacity is limited, in part, by the limited number of physicians who offer office based OUD tr...

    Authors: Adriane M. dela Cruz, Robrina Walker, Ronny Pipes, Sidarth Wakhlu and Madhukar H. Trivedi
    Citation: Addiction Science & Clinical Practice 2021 16:12
  9. Most people with opioid use disorder (OUD) never receive treatment. Medication treatment of OUD in primary care is recommended as an approach to increase access to care. The PRimary Care Opioid Use Disorders t...

    Authors: Cynthia I. Campbell, Andrew J. Saxon, Denise M. Boudreau, Paige D. Wartko, Jennifer F. Bobb, Amy K. Lee, Abigail G. Matthews, Jennifer McCormack, David S. Liu, Megan Addis, Andrea Altschuler, Jeffrey H. Samet, Colleen T. LaBelle, Julia Arnsten, Ryan M. Caldeiro, Douglas T. Borst…
    Citation: Addiction Science & Clinical Practice 2021 16:9
  10. The COVID-19 pandemic has resulted in unparalleled societal disruption with wide ranging effects on individual liberties, the economy, and physical and mental health. While no social strata or population has b...

    Authors: Ethan Cowan, Maria R. Khan, Siri Shastry and E. Jennifer Edelman
    Citation: Addiction Science & Clinical Practice 2021 16:4
  11. There is growing public health concern around the potential impact of the opioid crisis on efforts to eradicate HIV. This secondary analysis seeks to determine if those who report opioids as their primary prob...

    Authors: Lacey Critchley, Adam Carrico, Natalie Gukasyan, Petra Jacobs, Raul N. Mandler, Allan E. Rodriguez, Carlos del Rio, Lisa R. Metsch and Daniel J. Feaster
    Citation: Addiction Science & Clinical Practice 2020 15:19